Related Experiment Video
Updated: Jan 23, 2026
09:57
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
9.1K
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
Carlo Garofalo1, Silvio Borrelli2, Maria Elena Liberti3
1Division of Nephrology, University of Campania "Luigi Vanvitelli", 80137 Naples, Italy. carlo.garofalo@unicampania.it.
Medicina (Kaunas, Lithuania)
|June 20, 2019
Summary
Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) show promise in managing diabetic kidney disease (DKD). These drugs offer nephroprotective benefits, improving renal outcomes alongside glycemic and cardiovascular control.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic kidney disease (DKD) presents a growing global health challenge.
- Current treatments, primarily renin-angiotensin system inhibitors, have limited efficacy.
- Novel therapeutic strategies for nephroprotection in DKD are urgently needed.
Purpose of the Study:
- To review the current understanding and clinical effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) in managing diabetic kidney disease.
- To evaluate the nephroprotective effects of SGLT2-i as observed in recent clinical trials.
- To discuss the pathophysiological basis and clinical application of SGLT2-i therapy.
Main Methods:
- Review of recent clinical trials investigating SGLT2 inhibitors in type 2 diabetes mellitus and chronic kidney disease.
- Analysis of secondary endpoints related to renal outcomes (glomerular filtration rate, albuminuria).
- Synthesis of existing literature on the efficacy and safety of SGLT2 inhibitors.
Main Results:
- SGLT2 inhibitors demonstrate consistent positive effects on hyperglycemia and cardiovascular outcomes.
- Significant nephroprotective effects were observed, evidenced by improvements in renal function and albuminuria.
- While adverse effects exist, the overall benefit-risk profile favors the use of SGLT2 inhibitors.
Conclusions:
- SGLT2 inhibitors represent a significant advancement in managing DKD, offering dual benefits for glycemic and renal health.
- Further research and clinical evaluation, including trials in diverse CKD populations, continue to refine our understanding of SGLT2-i.
- SGLT2 inhibitors are emerging as a key therapeutic option for patients with DKD and related complications.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
01:29Self-Efficacy
210
Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
210
02:19Buffer Effectiveness
54.9K
Buffer solutions do not have an unlimited capacity to keep the pH relatively constant . Instead, the ability of a buffer solution to resist changes in pH relies on the presence of appreciable amounts of its conjugate weak acid-base pair. When enough strong acid or base is added to substantially lower the concentration of either member of the buffer pair, the buffering action within the solution is compromised.
The buffer capacity is the amount of acid or base that can be added to a given volume...
The buffer capacity is the amount of acid or base that can be added to a given volume...
54.9K
03:26Framing Effects
7.9K
Information is everywhere and its presentation—such as how and when items are presented—can impact our perceptions and decisions surrounding the info. This broad concept umbrellas framing effects—influences that occur due to the way information is framed in its appearance, whether it’s purely the order or the specific wording of a message. Let’s take a look at numerous ways in which two versions of something can objectively say the same thing, yet we respond in...
7.9K
01:23Dipeptidyl Peptidase 4 Inhibitors
616
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
616
01:22Dose-Response Relationship: Potency and Efficacy
6.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.4K